Production (Stage)
Sharp Therapeutics Corp.
SHRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 782.50K | 446.90K | 715.20K | 983.50K | 511.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.25M | 2.54M | 2.71M | 2.88M | 2.30M |
| Operating Income | -3.25M | -2.54M | -2.71M | -2.88M | -2.30M |
| Income Before Tax | -5.29M | -3.26M | -4.09M | -4.91M | -3.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.29 | -3.26 | -4.09 | -4.91 | -3.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.29M | -3.26M | -4.09M | -4.91M | -3.97M |
| EBIT | -3.25M | -2.54M | -2.71M | -2.88M | -2.30M |
| EBITDA | -3.24M | -2.52M | -2.69M | -2.84M | -2.23M |
| EPS Basic | -13.09 | -21.81 | -21.91 | -22.01 | -15.21 |
| Normalized Basic EPS | -6.58 | -10.56 | -10.61 | -10.65 | -7.54 |
| EPS Diluted | -13.09 | -21.81 | -21.91 | -22.01 | -15.21 |
| Normalized Diluted EPS | -6.58 | -10.56 | -10.61 | -10.65 | -7.54 |
| Average Basic Shares Outstanding | 64.07M | 35.99M | 26.69M | 17.38M | 17.38M |
| Average Diluted Shares Outstanding | 64.07M | 35.99M | 26.69M | 17.38M | 17.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |